Project Grant R01AI192524
Award Date
7/23/25
Completion Date
6/30/29
Dollars Obligated
$2.9M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This Project Grant award of $461,250 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research at Yale University to understand antibiotic tolerance in Mycobacterium tuberculosis (MTB). The key objectives are to: 1) Identify the subcellular environments and carbon sources associated with drug-tolerant MTB, and 2) Develop in vitro culture conditions mimicking these environments for future...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA program 93.855 "Allergy and Infectious Diseases Research," is providing $813,373 to Rutgers, The State University of New Jersey to conduct research on developing new classes of pyrazinoic acid prodrugs against pyrazinamide-resistant Mycobacterium tuberculosis. The goal is to characterize the diverse set of Mycobacterium tuberculosis amidases and the compound structures...
This Project Grant award of $176,152, provided by the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify new drug targets against drug-tolerant strains of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The research aims to study the role of lipid metabolism and host-pathogen interactions in conferring drug tolerance to MTB strains with deficient glycerol...
This federal Project Grant award of $787,171 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel 1,2,4-triazole and pyrrolidine compounds as potential treatments for tuberculosis (TB). The primary objectives are to demonstrate preclinical proof-of-concept for these compound classes, optimize their pharmacological properties, and investigate their unique mechanism of action compared...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $404,108 to the University of California, Davis (UC Davis) to identify genetic and signaling pathways that enable Mycobacterium tuberculosis (MTB) persister cells to survive antibiotic treatment. The award aims to apply genetic and proteomic approaches to uncover the core mechanisms driving MTB...
This Project Grant award of $774,881, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855), supports research to develop pro-apoptotic small molecule host-directed therapies (HDTs) for the treatment of pulmonary tuberculosis (TB). The research aims to utilize these novel HDTs to shorten TB treatment duration, enhance antibiotic penetration, and prevent post-TB lung disease. The project leverages...
This Project Grant award of $162,000.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to characterize the role of plasmacytoid dendritic cells (pDCs) in Mycobacterium tuberculosis (MTB) infection. The goal is to identify pDC-specific therapeutic targets that could lead to host-directed therapies for tuberculosis. The 2-year project, running from Jun 1, 2025 to May 31, 2027, will leverage advanced...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $565,149 to Health Research, Inc. Wadsworth Center Division to conduct research on RNA-based regulatory mechanisms in Mycobacterium tuberculosis (MTB). The primary objectives are to: Define the regulatory interactions of the sRNA MCR11 and its impact on gene expression in MTB. Characterize the roles of RNA-ABMR...
This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $800,200 to study the mechanisms of interferon-gamma (IFN-γ)-independent T cell and B cell-mediated protection against tuberculosis (TB) in humans. The research aims to elucidate the IFN-γ-independent T cell response and characterize the B cell, antibody, and T follicular helper (Tfh) cell responses in...